Tissue plasminogen activator, which is used to treat blood clots, may help severely ill patients with COVID-19 who are in respiratory failure, according to a new paper.
CVS Caremark’s new quantity limits will not affect members who are already receiving these medications for their approved uses.
Convalescent plasma, hydroxychloroquine, and remdesivir among the potential COVID-19 treatment pathways being pursued.
A study investigated the use of lopinavir-ritonavir for the potential treatment of hospitalized patients with severe COVID-19.
The trials demonstrated a significant decrease in 24-hour coughs per hour versus placebo at 12 and 24 weeks.
Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.
After a steady climb, a new study showed that death rates for melanoma in the United States have dropped over the last few years.
The announcement follows their previous commitment to offering COVID-19 testing at local hospitals.
Pediatricians stress the importance of understanding the effects of COVID-19 on children.
Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).